Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807097 | 0.92 | ITGB2 (0.42) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL6807751 | 0.86 | CYP3A4 (0.40) | GAAITGA4ITGB1 | |
| SCHEMBL6808040 | 0.85 | GAA (0.40) | GAAITGA4ITGB1ITGB7ATM | |
| SCHEMBL6808223 | 0.84 | ITGA4 (0.38) | GAAITGA4ITGB1ITGB7ITGB2 | |
| SCHEMBL6808623 | 0.84 | CYP3A4 (0.42) | GAAITGA4ITGB1ITGB2ICAM1 | |
| SCHEMBL6807946 | 0.83 | GAA (0.44) | GAAITGB2ICAM1ITGAL | |
| SCHEMBL6807128 | 0.83 | ITGB2 (0.45) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL6804283 | 0.82 | ITGB2 (0.41) | ITGA4ITGB1ITGB7ITGB2ICAM1 | |
| SCHEMBL6808563 | 0.82 | ATM (0.39) | GAAATML3MBTL1 | |
| SCHEMBL6807625 | 0.82 | MEN1 (0.47) | GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | GAA 2094/4885ITGA4 221/4885ITGB1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.